SEC Form 4 · accession 0001273902-16-000231

CIRRUS LOGIC, INC. · CRUS

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — President & CEO · Director

Period of report

Sep 12, 2016

Accepted (ET)

Sep 13, 2016 · 5:10 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000772406

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock	Sep 12, 2016	M	50,000	$7.87	A	179,680	D
Common Stock^F2	Sep 12, 2016	S	50,000	$48.555	D	129,680	D
Common Stock	Sep 12, 2016	M	40,156	$7.87	A	169,836	D
Common Stock^F3	Sep 12, 2016	S	40,156	$48.5805	D	129,680	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Non-Qualified Stock Option (right to buy)^F5,F4	$7.87	Sep 12, 2016	M	50,000	D	—	Jun 6, 2017	Common Stock	50,000	40,156	D
Non-Qualified Stock Option (right to buy)^F5,F4	$7.87	Sep 12, 2016	M	40,156	D	—	Jun 6, 2017	Common Stock	40,156	0	D

F1This transaction was made pursuant to a Rule 10b5-1 Plan adopted by the reporting person on November 24, 2015, as amended on May 31, 2016 and August 23, 2016.
F2The price reported in Table I - Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.13 to $49.63. The reporting person will provide full information regarding the number of shares bought as each separate price within the ranges set forth in this footnote to any security holder of Cirrus Logic, Inc. or the staff of the SEC upon request.
F3The price reported in Table I - Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.07 to $49.625. The reporting person will provide full information regarding the number of shares bought as each separate price within the ranges set forth in this footnote to any security holder of Cirrus Logic, Inc. or the staff of the SEC upon request.
F4The option vested on a 4-year schedule: 25% of the shares became exercisable on 6/6/2008; the remaining 75% of the shares vested at a rate of 1/36th per month over the following 36 months so that the option was fully vested and exercisable on 6/6/2011. Only vested shares can be exercised under this option. The options were set to expire in 2017.
F5Dr. Rhode continues to beneficially own 717,703 shares, which includes 588,023 shares issuable upon exercise of vested stock options held by Dr. Rhode and 129,680 shares held directly.